Abstract
Aim:
To investigate the effect of recombined human glucagon-like peptide 1 (rhGLP-1 [7–36]) on the secretion and expression of amylin in Goto-Kakizaki (GK) rats.
Methods:
The GK rats were treated with rhGLP-1 (7–36) 56 and 133 μg·kg−1 subcutaneously for 12 weeks. The fasting and post-prandial blood glucose levels were measured. The plasma amylin concentration was measured by ELISA. The transcription levels of amylin and insulin mRNA were evaluated by fluorescent-quantitative-PCR. Immunohistochemistry was utilized to detect the amylin protein. Histological examination was assayed by light microscopy.
Results:
Treatment with rhGLP-1 (7–36) caused a significant reduction of post-prandial blood glucose levels in the GK rats (P<0.05). The plasma amylin levels of the GK rats were lower than those of Wistar rats after the glucose administration (P<0.01). Treatment with rhGLP-1 (7–36) exhibited a marked elevation of the glucose-stimulated plasma amylin level (P<0.05) and slight histological amelioration. The amylin expression was augmented in the rhGLP-1 (7–36)-treated GK rat pancreas. Amylin and insulin mRNA were also highly expressed in the treated GK rats (P<0.05). However, the ratio of amylin to insulin mRNA was significantly decreased by treatment with rhGLP-1 (7–36).
Conclusion:
RhGLP-1 (7–36) stimulates the secretion and expression of amylin, and exerts a beneficial effect on the ratio of amylin to insulin mRNA. These findings suggest that GLP-1 and GLP-1 analogs are ideal candidates for the treatment of type 2 diabetes.
Similar content being viewed by others
Article PDF
References
Marzban L, Park K, Verchere CB . Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 2003; 38: 347–51.
Jaikaran ET, Clark A . Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001; 1537: 179–203.
Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH . Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuron-peptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987; 84: 3881–5.
Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 1990; 39: 634–8.
Kahn SE, Andrikopoulos S, Verchere CB . Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999; 48: 241–53.
Ludvik B, Thomaseth K, Nolan JJ, Clodi M, Prager R, Pacini G . Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest 2003; 33: 316–22.
Verchere CB, D'Alessio DA, Prigeon RL, Hull RL, Kahn SE . The constitutive secretory pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat islet cells. Diabetes 2000; 49: 1477–84.
Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC, et al. Changes in amylin and amylin-like peptide concentrations and β-cell function in response to sulfonylurea or insulin therapy in NIDDM. Diabetes Care 1998; 21: 810–6.
Dhanvantari S, Izzo A, Jansen E, Brubaker PL . Coregulation of glucagon-like peptide-1 synthesis with proglucagon and prohormone convertase 1 gene expression in enteroendocrine GLUTag cells. Endocrinology 2001; 142: 37–42.
Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ . Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609–13.
Brubaker PL, Drucker DJ . Mini review: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145: 2653–9.
Zander M, Madsbad S, Madsen JL, Holst JJ . Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824–30.
Kjems LL, Holst JJ, Vølund A, Madsbad S . The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380–6.
Portha B, Serradas P, Bailbé D, Suzuki K, Goto Y, Giroix MH . β-Cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes 1991; 40: 486–91.
Ostenson CG, Khan A, Abdel-Halim SM, Guenifi A, Suzuki K, Goto Y, et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 1993; 36: 3–8.
Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745–52.
Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh C, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 1997; 99: 2883–9.
Buse JB, Weyer C, Maggs DG . Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes 2002; 20: 137–44.
Rotondo F, Vidal S, Bell D, Horvath E, Kovacs K, Scheithauer BW, et al. Immunohistochemical localization of amylin in human pancreas, thyroid, pituitary and their tumors. Acta Histochem 2003; 105: 303–7.
Leckström A, Ostenson CG, Efendiæ S, Arnelo U, Permert J, Lundquist I, et al. Increased storage and secretion of islet amyloid polypeptide relative to insulin in the spontaneously diabetic GK rat. Pancreas 1996; 13: 259–67.
Ferrannini E . Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19: 477–90.
Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–9.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93.
Drucker DJ . Mini review: the glucagon-like peptides. Endocrinology 2001; 142: 521–7.
Kieffer TJ, Habener JF . The glucagon-like peptides. Endocr Rev 1999; 20: 876–913.
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ . Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126–31.
Leahy JL, Fineman MS . Impaired phasic insulin and amylin secretion in diabetes rats. Am J Physiol 1998; 275: E457–62.
Cluck MW, Murphy LO, Olson J, Knezetic JA, Adrian TE . Amylin gene expression mediated by cAMP/PKA and transcription factors HNF-1 and NFY. Mol Cell Endocrinol 2003; 210: 63–75.
Gu Q, Gao X . Effect of recombined human glucagon-like peptide-1 on body weight, blood glucose metabolism and β-cell function and mass in GK rat. Fudan Univ J Med Sci 2007; 34: 111–5.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Project supported by a research fund for the Doctoral Program of Higher Education (No 2004-024-6069) and the Shanghai Science and Technology Development Foundation (No 064909002).
Rights and permissions
About this article
Cite this article
Weng, Hb., Gu, Q., Liu, M. et al. Increased secretion and expression of amylin in spontaneously diabetic Goto-Kakizaki rats treated with rhGLP-1 (7–36). Acta Pharmacol Sin 29, 573–579 (2008). https://doi.org/10.1111/j.1745-7254.2008.00782.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00782.x